Literature DB >> 7679865

Current progress in the development of the B subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes.

T O Nashar1, T Amin, A Marcello, T R Hirst.   

Abstract

The development of non-living carrier systems for delivery of protective antigens or epitopes to the immune system represents both a fundamental and an applied aspect of vaccinology. A wide range of carrier systems, ranging from inert supports to proteins that exert direct immunomodulating effects on the immune response, are being studied. In this overview we describe the current progress in the development of the B-subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as potential protein carriers for the oral delivery of chemically and genetically attached antigens and epitopes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679865     DOI: 10.1016/0264-410x(93)90023-q

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  High level expression of a functionally active cholera toxin B: rabies glycoprotein fusion protein in tobacco seeds.

Authors:  Siddharth Tiwari; Devesh K Mishra; Sribash Roy; Ankit Singh; P K Singh; Rakesh Tuli
Journal:  Plant Cell Rep       Date:  2009-10-10       Impact factor: 4.570

2.  Oral immunization with the saliva-binding region of Streptococcus mutans AgI/II genetically coupled to the cholera toxin B subunit elicits T-helper-cell responses in gut-associated lymphoid tissues.

Authors:  N Toida; G Hajishengallis; H Y Wu; M W Russell
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

Review 3.  Two decades of plant-based candidate vaccines: a review of the chimeric protein approaches.

Authors:  Ruth Elena Soria-Guerra; Leticia Moreno-Fierros; Sergio Rosales-Mendoza
Journal:  Plant Cell Rep       Date:  2011-04-20       Impact factor: 4.570

Review 4.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

5.  Cholera and severe toxigenic diarrhoeas.

Authors:  D R Nalin
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

6.  Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis.

Authors:  T G Blanchard; N Lycke; S J Czinn; J G Nedrud
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

Review 7.  Recent progress concerning CpG DNA and its use as a vaccine adjuvant.

Authors:  Hidekazu Shirota; Dennis M Klinman
Journal:  Expert Rev Vaccines       Date:  2013-11-26       Impact factor: 5.217

8.  Immunogenicity of the B monomer of Escherichia coli heat-labile toxin expressed on the surface of Streptococcus gordonii.

Authors:  S Ricci; D Medaglini; C M Rush; A Marcello; S Peppoloni; R Manganelli; G Palú; G Pozzi
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

9.  Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants.

Authors:  G Douce; C Turcotte; I Cropley; M Roberts; M Pizza; M Domenghini; R Rappuoli; G Dougan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

10.  Specific inhibition of herpes virus replication by receptor-mediated entry of an antiviral peptide linked to Escherichia coli enterotoxin B subunit.

Authors:  A Marcello; A Loregian; A Cross; H Marsden; T R Hirst; G Palù
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.